GLP-1 dose escalation scheduler

Generate week-by-week dose escalation schedules for GLP-1 receptor agonists. Follow manufacturer-recommended titration protocols to minimize side effects.

ReconBlendReverseGLP-1DurationHalf-life

GLP-1 scheduler

mg/mL
$
Current week0.25 mg
Week 1Phase: Month 1
Next escalation: 0.5 mg in 4 weeks (week 5)
WkDose
10.25 mg←
20.25 mg
30.25 mg
40.25 mg
50.5 mg↑
60.5 mg
70.5 mg
80.5 mg
91 mg↑
101 mg
111 mg
121 mg
131.7 mg↑
141.7 mg
151.7 mg
161.7 mg
172.4 mg↑
182.4 mg
192.4 mg
202.4 mg

Supported protocols

Semaglutide (Wegovy)

GLP-1 agonist ↗

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg

Source: FDA Label

Semaglutide (Ozempic)

GLP-1 agonist ↗

0.25 → 0.5 → 1.0 mg

Source: FDA Label

Tirzepatide (Mounjaro)

Dual GIP/GLP-1 ↗

2.5 → 5.0 → 7.5 → 10.0 → 12.5 → 15.0 mg

Source: FDA Label

Retatrutide (Phase II)

Triple agonist ↗

1 → 2 → 4 → 8 → 12 mg

Source: PMID: 37351564

SemaglutideGLP-1 receptor agonist

Mimics the GLP-1 incretin hormone with 94% sequence homology. Once-weekly dosing via 7-day albumin-bound half-life.

15–17%Weight loss
7 daysHalf-life
→
TirzepatideDual GIP/GLP-1 agonist

First dual GIP + GLP-1 agonist - activates two incretin pathways simultaneously for superior fat loss and glycemic control.

Up to 22.5%Weight loss
5 daysHalf-life
→
RetatrutideTriple GLP-1/GIP/glucagon agonist

Triple incretin agonist - the first to also activate the glucagon receptor, adding increased energy expenditure to the GLP-1 + GIP mechanism.

Up to 28.7%Weight loss
6 daysHalf-life
→